Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study.
Klaesson
S
S
Department of Transplantation Surgery, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden.
Ringdén
O
O
Ljungman
P
P
Lönnqvist
B
B
Wennberg
L
L
D016026:Bone Marrow Transplantation / Q000276:immunology; D002066:Busulfan / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D017707:Erythrocyte Transfusion / Q000191:economics; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
D011994:Recombinant Proteins; D004921:Erythropoietin; D002066:Busulfan